Patent protection for semaglutide expires in India in March 2026, triggering a rush among Indian drugmakers to prepare lower-cost versions ...
Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March under ...
Patent protection for semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's diabetes drug Ozempic and ...
Dr Reddy’s Laboratories is likely to launch its generic semaglutide injection in the country in March under the brand name ...
The country's anti-obesity market is headed for a pricing shake-up, with a clutch of pharma companies readying plans to launch affordable v.
Analysts say Novo Nordisk’s new obesity drug may be obsolete before it hits the shelves, underlining a massive fall from grace for the company behind the weight loss boom.
While everyone seems to be talking about 'Ozempic face' - the gaunt, aged look from rapid weight loss drugs - fewer are aware ...
Novo Nordisk A/S still looks like a buy: oral Wegovy growth, solid global demand, 13x forward P/E, and buybacks support upside. Click for this NVO stock update.
2d
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed ...
Doctors call Wegovy’s new weight loss pill a game changer in the fight against obesity, but some experts are urging patients to be cautious.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results